§ 40:1086.12 — Neonatal opiate withdrawal syndrome pilot project

Louisiana § 40:1086.12

• Jurisdiction: Louisiana
• Title 40: Public Health and Safety

Text

§1086.12. Neonatal opiate withdrawal syndrome pilot project
A. For the purpose of this Section, the following definitions apply:
(1) "Department" means the Louisiana Department of Health.
(2) "Infant" includes both a newborn and an infant.
(3) "Neonatal opiate withdrawal syndrome" means the postnatal opioid withdrawal
experienced by an infant who is exposed in utero to prescribed or illicit opioids or agents
used to treat maternal opioid addiction.
B.(1) The department shall establish an evidence-based pilot project conducted by
a multi-disciplinary team to treat infants with neonatal opiate withdrawal syndrome by
providing care options that are safe alternatives to the intensive care unit in existing
community or hospital settings for eligible mother-infant dyads. This pilot shall prioritize
co-location of the mother-infant dyad, maternal access to evidence-based treatment of
substance use disorder, and promotion of practices that minimize harm and improve
outcomes in infants, in keeping with up-to-date clinical evidence.
(2) In order to scale evidence-based best practices statewide, the department, in
coordination with Department of Children and Family Services, shall convene stakeholders
and providers from around the state, including but not limited to the Louisiana Commission
on Perinatal Care and Prevention of Infant Mortality and the Louisiana Perinatal Quality
Collaborative, in order to promote evidence-based care of infants with neonatal opiate
withdrawal syndrome.
C. The department shall study comparative outcomes, risks, benefits, and cost
differentials for the treatment of infants with neonatal opiate withdrawal syndrome in
hospital and community settings included in this pilot program.
D. The department may provide access to United States Food and Drug
Administration approved medication-assisted treatment including agonist, partial-agonist,
and antagonist medications for the treatment of opioid use disorders, in conjunction with
detoxification services for females with a history of giving birth to neonatal abstinence
syndrome affected infants.
E. The department shall take all steps necessary to implement this Section, including
but not limited to the promulgation of rules and regulations in accordance with the
Administrative Procedure Act, and may seek a waiver from the Centers for Medicare and
Medicaid Services if needed.
F. The pilot project may be administered consistent with the Controlled Substance
Act, as amended by Section 303 of the Comprehensive Addiction and Recovery Act of 2016.
G. This pilot project is subject to specific appropriation by the legislature.

Legislative History

Acts 2018, No. 174, §1.